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Introduction
PD-L1-negative tumors assessed by immunohistochem-
istry often still respond to PD-1 blockade. PD-L1 is
inducible by interferon, therefore, absolute negative
tumors are the ones unable to up-regulate PD-L1 in
response to interferons. Genetic mutations in the inter-
feron receptor signaling pathway leading to loss of PD-
L1 up-regulation were hypothesized to exhibit innate
resistance to PD-1 blockade.
Experimental procedures
After optimization, 50 primary human melanoma cell
lines were exposed to interferons (alpha, beta and
gamma) and PD-L1 expression was measured. Interferon
signaling was assessed by single cell phospho-proteomics,
pSTAT1 (Y701), pSTAT3, pSTAT5, pSTAT6 expression
level by flow cytometry (FACS LSRII). Western blot
assessed JAK1/JAK2/IRF1 as well as STAT/pSTAT expres-
sion and Whole exome sequencing was performed by next
generation sequencing for three selected melanoma cell
lines and on biopsies from 25 patients with advanced mela-
noma treated with anti-PD-1 therapy.
Results
Three out of 50 melanoma cell lines were unable to up-
regulate PD-L1 in response to interferon gamma; two of
them had disruptive mutations in JAK1 or JAK2, and a
third one had a defect in expression of IRF1 in response
to interferons. Western blot analysis confirmed loss of
function for the JAK1/JAK2 mutations and loss of
downstream IRF1/STAT1/3/5 phosphorylation events.
Whole exome sequencing of biopsies from 15 patients
with metastatic melanoma who had objective response
to PD-1 blockade (pembrolizumab) showed no homozy-
gous inactivating mutations in interferon signaling path-
way genes. Interestingly, one patient with the highest
mutational load out of 10 patients without clinical
response to PD-1 blockade had an amplified allele of
JAK1 with a P429S mutation in the src-homology (SH2)
domain. A cell line derived from this patient showed
lack of sustained up-regulating of PD-L1 expression in
response to interferon gamma by, and Western blot
confirmed loss of JAK1 expression. Immunohistochem-
istry of tumor biopsy for this patient showed few CD8+
T cells.
Conclusions
This study has defined genetic mechanisms of innate
resistance to PD-1 blockade which lead to inhibition of
adaptive PD-L1 expression in patients with advanced
melanoma. This work suggests lack of interferon-gamma
induced PD-L1 upregulation has the potential to be a
negative selective marker for PD-1 blockade therapy.
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